NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $12.26 -0.04 (-0.31%) Closing price 03:59 PM EasternExtended Trading$12.26 -0.01 (-0.06%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dr. Reddy's Laboratories Stock (NYSE:RDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RDY alerts:Sign Up Key Stats Today's Range$12.17▼$12.3550-Day Range$11.37▼$12.6452-Week Range$11.36▼$15.67Volume3.17 million shsAverage Volume2.45 million shsMarket Capitalization$10.23 billionP/E Ratio27.87Dividend Yield0.49%Price TargetN/AConsensus RatingReduce Company Overview Dr. Reddy’s Laboratories Limited is a Hyderabad, India-based pharmaceutical company that develops, manufactures and markets medicines. Its portfolio includes generic pharmaceuticals, active pharmaceutical ingredients (APIs), biosimilars and proprietary products, as well as over-the-counter and consumer health offerings in selected markets. Founded in 1984 by Dr. Kallam Anji Reddy, the company began with a focus on APIs and expanded into finished-dose medicines and international pharmaceutical markets. Dr. Reddy’s products span therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology. Dr. Reddy’s serves patients and healthcare providers in India, the United States, Europe and other emerging markets. The company operates through research and development, manufacturing and commercial operations across multiple regions. G. V. Prasad serves as co-chairman and managing director, while Erez Israeli serves as chief executive officer.AI Generated. May Contain Errors. Read More Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 38% of companies evaluated by MarketBeat, and ranked 692nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth26.67% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 26.67% in the coming year, from $0.45 to $0.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 27.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 27.88, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.71.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 2.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.54% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.01.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 21.18%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 13.64%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.53% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. News and Social Media2.8 / 5News Sentiment0.56 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by Institutions3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDY Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 24 at 6:38 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 22 at 8:54 PM | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 25 at 1:00 AM | Porter & Company (Ad)Takeda, Dr Reddy's to launch dengue vaccine QDENGA in India by 2027September 18, 2026 | msn.comIndia's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in IndiaSeptember 17, 2026 | reuters.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 17, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 15, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 8, 2026 | globenewswire.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $14.03 at the beginning of 2026. Since then, RDY stock has decreased by 12.6% and is now trading at $12.2650. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Ltd (NYSE:RDY) announced its quarterly earnings results on Thursday, July, 23rd. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.03. The firm earned $850.26 million during the quarter, compared to analysts' expectations of $850.56 million. Dr. Reddy's Laboratories had a net margin of 10.15% and a trailing twelve-month return on equity of 9.49%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Shares of Dr. Reddy's Laboratories split on the morning of Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly issued shares were issued to shareholders after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' top institutional investors include B. Metzler seel. Sohn & Co. AG (0.05%), Corient Private Wealth LP (0.03%), Sequoia Financial Advisors LLC (0.02%) and Nykredit A S (0.02%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/23/2026Today9/25/2026Next Earnings (Estimated)10/23/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RDY's financial health is in the Red zone, according to TradeSmith. RDY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,527Year Founded1984Profitability EPS (Trailing Twelve Months)$0.44 Trailing P/E Ratio27.87 Forward P/E Ratio27.25 P/E Growth2.62Net Income$456 million Net Margins10.15% Pretax Margin11.58% Return on Equity9.49% Return on Assets6.32% Debt Debt-to-Equity Ratio0.03 Current Ratio1.90 Quick Ratio1.39 Sales & Book Value Annual Sales$3.58 billion Price / Sales2.86 Cash Flow$0.83 per share Price / Cash Flow14.84 Book Value$4.86 per share Price / Book2.52Miscellaneous Outstanding Shares834,670,000Free Float817,978,000Market Cap$10.23 billion OptionableOptionable Beta0.28 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:RDY) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
